On September 19, 2018 Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) reported its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences (Press release, Aurinia Pharmaceuticals, SEP 19, 2018, View Source [SID1234529490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will be webcast live and can be accessed via the investor section of the Aurinia website, www.auriniapharma.com. A replay of each presentation will also be archived on the site following the event.

Monday, October 1, 2018, Aurinia will present at the Cantor Fitzgerald 4th Annual Healthcare Conference in New York City at 8:55am ET.

Tuesday, October 2, 2018, Aurinia will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York City at 3:30pm ET.

On September 19, 2018 AskAt Inc. reported that AskAt received the decision to grant a European patent dated September 13, 2018 from the European Patent Office (EPO) in connection with the Application No. 15182580.9, a use patent of EP4 receptor antagonist for the treatment of Cancer (Press release, AskAt, SEP 19, 2018, View Source [SID1234535046]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 19, 2018 Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, reported that it has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T Cell (CAR-T) therapies for the treatment of solid and hematological cancers (Press release, Abzena, SEP 19, 2018, View Source [SID1234529491]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the agreement Abzena will humanize monoclonal antibodies using its Composite Human Antibody technology. This technology combines humanization and deimmunisation technologies to generate fully-humanized therapeutic antibodies devoid of CD4+ T cell epitopes.

Tmunity will use the humanised antibodies to develop CAR-T engineered products. CAR-T therapy is an innovative therapeutic form of personalised medicine in which a patient’s own T-cells are genetically modified to express an antigen recognizing CAR on the surface of the T cell. When the CAR-T encounters a cancer cell expressing the cognate antigen, the CAR-T is activated releasing cytokines that kill the cancer cell. CAR-T therapies have been successfully developed for the treatment of hematological cancers, a success that Tmunity is seeking to duplicate in solid tumors and other hematological malignancies.

The research and license agreement between Abzena and Tmunity also includes developability assessment to assess for any potential sequence liabilities that would affect quality of the product and EpiScreen, Abzena’s ex-vivo immunogenicity assessment platform.

Under the terms of the licence agreement Abzena will also be due milestone payments should products containing any of the humanized antibody sequences reach IND acceptance.

Campbell Bunce, SVP Scientific Operations of Abzena, said:

"We are delighted to be working with such an innovative organisation as Tmunity, to use our Composite Human Antibody platform to help design superior CARs for their CAR-T products. We believe that reducing the risk of immunogenicity of the receptor will contribute to a reduced risk profile for this exciting and potent treatment for cancer."

"Innovative use of our proprietary technology for an emerging and revolutionary drug platform like CAR-T, and utilisation of our protein engineering, immunology and bioanalytics expertise, is a great example of our ability to provide world-class support to our partners."

On September 19, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 16th, to review third-quarter results (Press release, Johnson & Johnson, SEP 19, 2018, View Source [SID1234529548]). Joseph J. Wolk, Executive Vice President, Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include the following executives: Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices; Jorge Mesquita, Executive Vice President, Worldwide Chairman, Consumer; and Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors and other interested parties can access the webcast/conference call in the following ways:

The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

By telephone: for both "listen-only" participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-869-3847. For participants outside the U.S., the dial-in number is 201-689-8261.

A replay of the conference call will be available until approximately 12:00 a.m. on October 24, 2018. The replay dial-in number for U.S. participants is 877-660-6853. For participants outside the U.S., the replay dial-in number is 201-612-7415. The replay conference ID number for all callers is 13683425.

The press release will be available at approximately 6:45 a.m. (Eastern Time) the morning of the conference call.

On September 19, 2019 Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) ("Cotinga" or the "Company"), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported that Richard Ho, M.D., Ph.D., Chief Scientific Officer, will present data on COTI-2, Cotinga’s lead compound currently in a Phase 1b/2a trial, at the 11th International Symposium on Translational Research in Oncology taking place September 27-29, 2018 in Dublin, Ireland (Press release, Cotinga, SEP 19, 2018, View Source [SID1234533151]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Title: COTI-2: preclinical and early clinical results from an orally available small molecule targeting mutant p53
Presentation Date and Time: Saturday, September 29, 2018 11:45 AM – 12:15 PM Irish Standard Time
Presentation Location: Landsdowne Suite, Herbert Park Hotel, Ballsbridge, D4

Phase 1b/2a Trial of COTI-2
The ongoing trial focuses on evaluating COTI-2 as a combination therapy for the potential treatment of a wide spectrum of cancers. In 2017, the Company announced top-line data from the gynecological malignancies arm of the trial demonstrating monotherapy with COTI-2 was generally safe and well-tolerated. Monotherapy with COTI-2 also exhibited an encouraging pharmacokinetic/pharmacodynamic profile and signals of efficacy.

Primary outcome measures will evaluate safety and tolerability and determine the maximum tolerated dose and recommended Phase 2 dose for COTI-2 as a combination therapy. Secondary and exploratory outcome measures will evaluate pharmacokinetics and various signals of efficacy. Additional details are available on clinicaltrials.gov.